Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vasomotor Symptoms (VMS) Clear all
Terminated Phase 2 Interventional

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

NCT02049164
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
AR08, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
41 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
San Diego, California • Colorado Springs, Colorado • Lakeworth, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
74
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

NCT02040532
View directory record Official record
Conditions
Menopause, Hot Flashes, Vasomotor Disturbance
Interventions
Gabapentin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).

NCT07033013
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Dietary Supplement with actives
Dietary Supplement
Lead sponsor
Olly, PBC
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

NCT05325775
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)

NCT07535541
View directory record Official record
Conditions
Prostate Cancer, Hot Flashes
Interventions
VMS logging
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

NCT03541200
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
MT-8554
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Lean Pork on Endothelial Function in Perimenopause

NCT06976112
View directory record Official record
Conditions
Cardiovascular Outcome, Overweight and Obese Women, Perimenopausal Women, Vasomotor Symptoms (VMS)
Interventions
Pork Diet, Plant Diet
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

NCT06949553
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No study intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

One Week Clinical Study in Subjects With Menopausal Symptoms

NCT06794021
View directory record Official record
Conditions
Healthy, Menopause
Interventions
Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo
Dietary Supplement · Other
Lead sponsor
Olly, PBC
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States

NCT07490431
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

NCT07042516
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
40 Years to 62 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Goji Berry and Vasomotor Symptoms Pilot Study

NCT07660315
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Goji Berry Juice Powder, Goji Berry Powder
Other
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Phase 2 Interventional

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT06957691
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulation, Placebo
Drug
Lead sponsor
Shehzad Basaria, M.D.
Other
Eligibility
40 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07408115
View directory record Official record
Conditions
Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions
JDS-HF3.0
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 11:25 AM EDT